The Facioscapulohumeral Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Facioscapulohumeral Muscular Dystrophy: An Overview
Facioscapulohumeral muscular dystrophy (FSHD) typically presents with weakness of the facial muscles, the stabilizers of the scapula, or the dorsiflexors of the foot. Severity is highly variable. Weakness is slowly progressive and approximately 20% of affected individuals eventually require a wheelchair. Life expectancy is not shortened.
Currently, there are no specific therapeutic cures for FSHD. But in 2010, the standard of care and management of FSHD were discussed and a census was agreed on at the 171st ENMC International Workshop. The main treatment strategies are divided into the different aspects of the muscle systems it affects.
Facioscapulohumeral Muscular Dystrophy Market Key Facts
Facioscapulohumeral muscular dystrophy (FSHD) is a rare familial disease with an estimated prevalence from 1/8,000 to 1/20,000. It is the third most common form of hereditary myopathy. Sposìto et al. (n.d.), found a prevalence in central Italy of 4.6:100,000.
FSHD commonly presents early in childhood with 95% of the affected individuals manifesting the disease by the age of 20. Muscle weakness is commonly non-specific but asymmetrical in occurrence.
No clear racial or ethnic differences are evident in FSHD but in one of the largest US registries, 95% of participants were white, 4% were Asian, and 0.9% were Native American.
Facioscapulohumeral Muscular Dystrophy Market
Facioscapulohumeral Muscular Dystrophy therapeutics market is expected to grow in the coming years owing to the increase in the research and development programs in the domain in recent years.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Facioscapulohumeral Muscular Dystrophy market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Facioscapulohumeral Muscular Dystrophy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Facioscapulohumeral Muscular Dystrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Facioscapulohumeral Muscular Dystrophy (FSHD) Epidemiology Segmentation
Total Incidence of FSHD
Sub-type specific Cases of FSHD
Treatable Cases of FSHD
Facioscapulohumeral Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facioscapulohumeral Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Facioscapulohumeral Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Facioscapulohumeral Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
Facioscapulohumeral Muscular Dystrophy Therapeutics Analysis
Several key companies are developing therapies for the treatment of Facioscapulohumeral Muscular Dystrophy. The approval of the emerging therapies will be a milestone for patients who have been suffering from Facioscapulohumeral Muscular Dystrophy.
Some of the key companies in the Facioscapulohumeral Muscular Dystrophy (FSHD) Market include:
Fulcrum Therapeutics
Dyne Therapeutics
Facio Therapies
Myocea
Avidity Biosciences
And many more
Facioscapulohumeral Muscular Dystrophy (FSHD) Therapies covered in the report include:
Losmapimod
GBC0905
Targets CK1
And many other
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Competitive Intelligence Analysis
4. Facioscapulohumeral Muscular Dystrophy Market Overview at a Glance
5. Facioscapulohumeral Muscular Dystrophy Disease Background and Overview
6. Facioscapulohumeral Muscular Dystrophy Patient Journey
7. Facioscapulohumeral Muscular Dystrophy Epidemiology and Patient Population
8. Facioscapulohumeral Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Facioscapulohumeral Muscular Dystrophy Unmet Needs
10. Key Endpoints of Facioscapulohumeral Muscular Dystrophy Treatment
11. Facioscapulohumeral Muscular Dystrophy Marketed Products
12. Facioscapulohumeral Muscular Dystrophy Emerging Therapies
13. Facioscapulohumeral Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Facioscapulohumeral Muscular Dystrophy Market Outlook (7 major markets)
16. Facioscapulohumeral Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Facioscapulohumeral Muscular Dystrophy Market.
18. Facioscapulohumeral Muscular Dystrophy Market Drivers
19. Facioscapulohumeral Muscular Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-market
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Bone Resorption Market“Bone Resorption Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Bone Resorption Market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
